ZOSTAVAX DIN 02315939
Status: Cancelled Post Market
Holder: MERCK CANADA INC
Health Canada record
| Active ingredient(s) | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 19400 PFU |
|---|---|
| Dosage form | Powder For Suspension |
| Route | Subcutaneous |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BK02 ZOSTER, LIVE ATTENUATED |
| Original market date | 16-Sep-2009 |
| Current status date | 06-May-2015 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02239199 | VARIVAX | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Powder For Solution | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT | Cancelled Post Market |
| 02240776 | VARIVAX II | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | Powder For Solution | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT | Cancelled Post Market |
| 02375516 | ZOSTAVAX II | MERCK CANADA INC | Powder For Suspension | VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 19400 PFU | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 9727 | 2008-08-22 | New Drug Submission (NDS) |